Detection of Spatiotemporal Clusters of COVID-19-Associated Symptoms and Prevention Using a Participatory Surveillance App: Protocol for the @choum Study.
COVID-19
SARS-CoV-2
digital health
digital surveillance
epidemiology
infectious disease
mHealth
mobile app
participatory surveillance
public health
space-time clustering
surveillance
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
06 Oct 2021
06 Oct 2021
Historique:
received:
14
05
2021
accepted:
19
07
2021
revised:
18
07
2021
pubmed:
28
8
2021
medline:
28
8
2021
entrez:
27
8
2021
Statut:
epublish
Résumé
The early detection of clusters of infectious diseases such as the SARS-CoV-2-related COVID-19 disease can promote timely testing recommendation compliance and help to prevent disease outbreaks. Prior research revealed the potential of COVID-19 participatory syndromic surveillance systems to complement traditional surveillance systems. However, most existing systems did not integrate geographic information at a local scale, which could improve the management of the SARS-CoV-2 pandemic. The aim of this study is to detect active and emerging spatiotemporal clusters of COVID-19-associated symptoms, and to examine (a posteriori) the association between the clusters' characteristics and sociodemographic and environmental determinants. This report presents the methodology and development of the @choum (English: "achoo") study, evaluating an epidemiological digital surveillance tool to detect and prevent clusters of individuals (target sample size, N=5000), aged 18 years or above, with COVID-19-associated symptoms living and/or working in the canton of Geneva, Switzerland. The tool is a 5-minute survey integrated into a free and secure mobile app (CoronApp-HUG). Participants are enrolled through a comprehensive communication campaign conducted throughout the 12-month data collection phase. Participants register to the tool by providing electronic informed consent and nonsensitive information (gender, age, geographically masked addresses). Symptomatic participants can then report COVID-19-associated symptoms at their onset (eg, symptoms type, test date) by tapping on the @choum button. Those who have not yet been tested are offered the possibility to be informed on their cluster status (information returned by daily automated clustering analysis). At each participation step, participants are redirected to the official COVID-19 recommendations websites. Geospatial clustering analyses are performed using the modified space-time density-based spatial clustering of applications with noise (MST-DBSCAN) algorithm. The study began on September 1, 2020, and will be completed on February 28, 2022. Multiple tests performed at various time points throughout the 5-month preparation phase have helped to improve the tool's user experience and the accuracy of the clustering analyses. A 1-month pilot study performed among 38 pharmacists working in 7 Geneva-based pharmacies confirmed the proper functioning of the tool. Since the tool's launch to the entire population of Geneva on February 11, 2021, data are being collected and clusters are being carefully monitored. The primary study outcomes are expected to be published in mid-2022. The @choum study evaluates an innovative participatory epidemiological digital surveillance tool to detect and prevent clusters of COVID-19-associated symptoms. @choum collects precise geographic information while protecting the user's privacy by using geomasking methods. By providing an evidence base to inform citizens and local authorities on areas potentially facing a high COVID-19 burden, the tool supports the targeted allocation of public health resources and promotes testing. DERR1-10.2196/30444.
Sections du résumé
BACKGROUND
BACKGROUND
The early detection of clusters of infectious diseases such as the SARS-CoV-2-related COVID-19 disease can promote timely testing recommendation compliance and help to prevent disease outbreaks. Prior research revealed the potential of COVID-19 participatory syndromic surveillance systems to complement traditional surveillance systems. However, most existing systems did not integrate geographic information at a local scale, which could improve the management of the SARS-CoV-2 pandemic.
OBJECTIVE
OBJECTIVE
The aim of this study is to detect active and emerging spatiotemporal clusters of COVID-19-associated symptoms, and to examine (a posteriori) the association between the clusters' characteristics and sociodemographic and environmental determinants.
METHODS
METHODS
This report presents the methodology and development of the @choum (English: "achoo") study, evaluating an epidemiological digital surveillance tool to detect and prevent clusters of individuals (target sample size, N=5000), aged 18 years or above, with COVID-19-associated symptoms living and/or working in the canton of Geneva, Switzerland. The tool is a 5-minute survey integrated into a free and secure mobile app (CoronApp-HUG). Participants are enrolled through a comprehensive communication campaign conducted throughout the 12-month data collection phase. Participants register to the tool by providing electronic informed consent and nonsensitive information (gender, age, geographically masked addresses). Symptomatic participants can then report COVID-19-associated symptoms at their onset (eg, symptoms type, test date) by tapping on the @choum button. Those who have not yet been tested are offered the possibility to be informed on their cluster status (information returned by daily automated clustering analysis). At each participation step, participants are redirected to the official COVID-19 recommendations websites. Geospatial clustering analyses are performed using the modified space-time density-based spatial clustering of applications with noise (MST-DBSCAN) algorithm.
RESULTS
RESULTS
The study began on September 1, 2020, and will be completed on February 28, 2022. Multiple tests performed at various time points throughout the 5-month preparation phase have helped to improve the tool's user experience and the accuracy of the clustering analyses. A 1-month pilot study performed among 38 pharmacists working in 7 Geneva-based pharmacies confirmed the proper functioning of the tool. Since the tool's launch to the entire population of Geneva on February 11, 2021, data are being collected and clusters are being carefully monitored. The primary study outcomes are expected to be published in mid-2022.
CONCLUSIONS
CONCLUSIONS
The @choum study evaluates an innovative participatory epidemiological digital surveillance tool to detect and prevent clusters of COVID-19-associated symptoms. @choum collects precise geographic information while protecting the user's privacy by using geomasking methods. By providing an evidence base to inform citizens and local authorities on areas potentially facing a high COVID-19 burden, the tool supports the targeted allocation of public health resources and promotes testing.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
DERR1-10.2196/30444.
Identifiants
pubmed: 34449403
pii: v10i10e30444
doi: 10.2196/30444
pmc: PMC8496683
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e30444Informations de copyright
©David De Ridder, Andrea Jutta Loizeau, José Luis Sandoval, Frédéric Ehrler, Myriam Perrier, Albert Ritch, Guillemette Violot, Marc Santolini, Bastian Greshake Tzovaras, Silvia Stringhini, Laurent Kaiser, Jean-François Pradeau, Stéphane Joost, Idris Guessous. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 06.10.2021.
Références
Nat Med. 2020 May;26(5):634-638
pubmed: 32273611
Am J Public Health. 2020 Jul;110(7):917
pubmed: 32463703
Nature. 2021 Jun;594(7863):408-412
pubmed: 33979832
J Geogr Syst. 2019 Jun;21(2):189-210
pubmed: 31171898
JMIR Public Health Surveill. 2020 Apr 7;6(2):e16119
pubmed: 32254042
J Travel Med. 2020 Nov 9;27(7):
pubmed: 32412064
Int J Med Inform. 2020 Nov;143:104263
pubmed: 32877853
JMIR Public Health Surveill. 2017 Sep 19;3(3):e66
pubmed: 28928112
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
Lancet Infect Dis. 2021 Mar;21(3):297
pubmed: 33581748
Swiss Med Wkly. 2020 Dec 16;150:w20457
pubmed: 33327003
Adv Med. 2014;2014:567049
pubmed: 26556417
Sci Total Environ. 2021 Sep 15;787:147483
pubmed: 34000545
Am J Public Health. 2015 Oct;105(10):2124-30
pubmed: 26270299
Nat Med. 2020 Aug;26(8):1183-1192
pubmed: 32770165
J Affect Disord. 2020 Feb 15;263:413-419
pubmed: 31969272
Lancet. 2021 Jun 12;397(10291):2234-2236
pubmed: 33932328
Geocarto Int. 2010 Oct 1;25(6):443-452
pubmed: 20953360
Spat Spatiotemporal Epidemiol. 2020 Aug;34:100354
pubmed: 32807396
Science. 2020 Jun 19;368(6497):1362-1367
pubmed: 32371477
Nature. 2020 Aug;584(7820):262-267
pubmed: 32512578
Lancet Digit Health. 2020 Aug;2(8):e393-e394
pubmed: 33328043
Science. 2018 Oct 5;362(6410):75-79
pubmed: 30287659
J Med Internet Res. 2020 Sep 29;22(9):e20283
pubmed: 32990635
Nat Med. 2020 Aug;26(8):1161-1165
pubmed: 32488218
JMIR Public Health Surveill. 2017 May 04;3(2):e26
pubmed: 28473308
Pervasive Mob Comput. 2021 Aug;75:101439
pubmed: 36569467
Emerg Infect Dis. 2015 Oct;21(10):1820-3
pubmed: 26401716
BMC Med. 2020 May 29;18(1):160
pubmed: 32466757
Soc Work Health Care. 2021;60(3):240-255
pubmed: 33407057
JMIR Public Health Surveill. 2020 May 26;6(2):e11512
pubmed: 32357126
JMIR Public Health Surveill. 2020 May 8;6(2):e19161
pubmed: 32369759
Front Public Health. 2021 Jan 27;8:626090
pubmed: 33614571
Nat Med. 2020 Jul;26(7):1037-1040
pubmed: 32393804
Nat Med. 2020 Dec;26(12):1829-1834
pubmed: 33020651
Appl Geogr. 2020 May;118:102202
pubmed: 32287518
BMJ. 2020 May 20;369:m2037
pubmed: 32434797
N Engl J Med. 2006 Oct 19;355(16):1741-2
pubmed: 17050904
JMIR Res Protoc. 2020 Dec 18;9(12):e24432
pubmed: 33301418
J Epidemiol Community Health. 2020 Nov;74(11):964-968
pubmed: 32535550
Stat Med. 2008 Nov 10;27(25):5111-42
pubmed: 18712778